Evaluation of assay methods to measure plasma ADAMTS13 activity in thrombotic microangiopathies

Thrombosis and Haemostasis

Volumn 105, Issue 2, 2011, Pages 381-385

  Palla, Roberta ^a   Valsecchi, Carla ^a   Bajetta, Mariateresa ^a   Spreafico, Marta ^a   De Cristofaro, Raimondo ^b   Peyvandi, Flora ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ASSAY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; INTERMETHOD COMPARISON; LETTER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESIDUAL VON WILLEBRAND FACTOR COLLAGEN BINDING ACTIVITY; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADAM PROTEINS; BIOLOGICAL ASSAY; COLLAGEN; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; PREDICTIVE VALUE OF TESTS; REGISTRIES; THROMBOTIC MICROANGIOPATHIES; TREATMENT OUTCOME; VON WILLEBRAND FACTOR;

EID: 79851489007     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-06-0417     Document Type: Letter

References (20)

1. Peyvandi F, Palla R, Lotta LA, et al. ADAMTS-13 assays in thrombotic thrombocytopenic purpura. J Thromb Haemost 2010; 8: 631-40.
2. Studt JD, Hovinga JA, Antoine G, et al. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood 2005; 105: 542-544. (Pubitemid 40070733)
3. Zhou Z, Han H, Cruz MA, et al. Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: A mechanism associated with sickle cell disease. Thromb Haemost 2009; 101: 1070-1077.
4. Meyer SC, Sulzer I, Lämmle B, et al. Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies. J Thromb Haemost 2007; 5: 866-867. (Pubitemid 46563591)
5. Eckmann CM, De Laaf RT, Van Keulen JM, et al. Bilirubin oxidase as a solution for the interference of hyperbilirubinemia with ADAMTS-13 activity measurement by FRETS-VWF73 assay. J Thromb Haemost 2007; 5: 1330-1331. (Pubitemid 46902141)
6. Raife TJ, Cao W, Atkinson BS, et al. Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site. Blood 2009; 114: 1666-1674.
7. Feys HB, Vandeputte N, Palla R, et al. Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura. J Thromb Haemost 2010; 8: 2053-2062.
8. Studt JD, Böhm M, Budde U, et al. Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods. J Thromb Haemost 2003; 1: 1882-1887.
9. Tripodi A, Chantarangkul V, Böhm M, et al. Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost 2004; 2: 1601-1609. (Pubitemid 40186177)
10. Kremer Hovinga JA, Mottini M, Lämmle B. Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay: comparison with other assay methods. J Thromb Haemost 2006; 4: 1146-1148.
11. Tripodi A, Peyvandi F, Chantarangkul V, et al. Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). J Thromb Haemost 2008; 6: 1534-1541.
12. Peyvandi F, Lavoretano S, Palla R, et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 2008; 93: 232-239. (Pubitemid 351397711)
13. Gerritsen HE, Turecek PL, Schwarz HP, et al. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost 1999; 82: 1386-1389.
14. Kokame K, Nobe Y, Kokubo Y, et al. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129: 93-100. (Pubitemid 40524057)
15. Mannucci PM, Peyvandi F. Thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome (congenital and acquired). In: Postgraduate Haematology. Blackwell Publishing Ltd, 2005. pp. 876-884.
16. Kato S, Matsumoto M, Matsuyama T, et al. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion 2006; 46: 1444-1452. (Pubitemid 44117975)
17. Shelat SG, Smith P, Ai J, et al. Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo. J Thromb Haemost 2006; 4: 1707-1717. (Pubitemid 44144797)
18. Starke R, Machin S, Scully M, et al. The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura. Br J Haematol 2006; 136: 649-655. (Pubitemid 46148203)
19. Kremer Hovinga JA, Vesely SK, Terrell DR, et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115: 1500-1511.
20. Feige MJ, Simpson ER, Herold EM, et al. Dissecting the alternatively folded state of the antibody Fab fragment. J Mol Biol 2010; 399: 719-730.